Kolexia
Petillon Marie-Odile Médecine générale
Petillon Marie-Odile
Médecine générale
Ifm
Paris, France
56 Activités
159 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Myélome multiple Tumeurs à plasmocytes Récidive tumorale locale Macroglobulinémie de Waldenström Anémie Neutropénie Translocation génétique Aberrations des chromosomes Gammapathie monoclonale de signification indéterminée

Collaborateurs

Voir plus
Leleu Xavier
Leleu Xavier
Hôpital La Miletrie, Poitiers, France
Moreau Philippe
Moreau Philippe
Hôpital Hôtel-Dieu Nantes, Nantes, France
Hulin Cyrille
Hulin Cyrille
Hôpital Haut-lévêque, Pessac, France
Facon Thierry
Facon Thierry
Hôpital Huriez, Lille, France

Industries

Voir plus
Janssen
5 collaboration(s)
Dernière en 2023
Pfizer
1 collaboration(s)
Dernière en 2023
{{person.topindus3.name}}
{{person.topindus3.tot}} collaboration(s)
Dernière en {{person.topindus3.last}}
{{person.topindus4.name}}
{{person.topindus4.tot}} collaboration(s)
Dernière en {{person.topindus4.last}}

Dernières activités

Voir plus
Ixazomib, Pomalidomide and Dexamethasone (IxPd) in Relapsed or Refractory Multiple Myeloma (RRMM) Characterized with High-Risk Cytogenetics. IFM 2014-01
65th ASH Annual Meeting Abstracts   02 novembre 2023
Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: the IFM 2020-04 study.
Haematologica   01 octobre 2023
Pomalidomide and dexamethasone until progression after first salvage therapy in multiple myeloma.
British journal of haematology   27 mars 2023
Clinical characteristics and outcome of 318 families with familial monoclonal gammopathy: A multicenter Intergroupe Francophone du Myélome study.
American journal of hematology   01 janvier 2023
Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myeloma.
Leukemia   14 octobre 2021
BVD: A Phase II Study of Bendamustine, Velcade and Dexamethasone (BVD) in the Treatment of Elderly Patients (>= 65 Years) With Multiple Myeloma in 1st Relapse or Refractory to 1st Line Therapy
Essai Clinique (Intergroupe Francophone du Myélome)   03 décembre 2020
Daratumumab and dexamethasone is safe and effective for triple refractory myeloma patients: final results of the IFM 2014-04 (Etoile du Nord) trial.
British journal of haematology   19 juin 2019
Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial.
Clinical cancer research : an official journal of the American Association for Cancer Research   03 mai 2019
Salvage therapy post pomalidomide-based regimen in relapsed/refractory myeloma.
Annals of hematology   12 janvier 2018
Prerequisite for hematopoietic cellular therapy programs to set up chimeric antigen receptor T-cell therapy (CAR T-cells): Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC).
Bulletin du cancer   23 novembre 2017